Drug Trial Radar · NCT04662931
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jul 14, 2021
Primary completion
Feb 14, 2024
Study completion Feb 14, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sickle cell disease (SCD) is a genetic blood disorder. Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in patients with SCD aged 16 years and older. The purpose of this local Phase IV study was to evaluate the safety of crizanlizumab specifically in Indian patients with SCD aged 16 years or older with a history of VOC leading to healthcare visit.
Conditions
- Sickle Cell Disease (SCD)
Interventions
crizanlizumabDrug
Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)Time frame: Up to 15 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Guwahati, Assam, India
Novartis Investigative Site
Raipur, Chhattisgarh, India
Novartis Investigative Site
Kozhikode, Kerala, India
Novartis Investigative Site
Bhubaneswar, Odisha, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.